Provenienza dei contatti di primo grado di Roman Schenk
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Recardio, Inc.
 Recardio, Inc. Pharmaceuticals: MajorHealth Technology Recardio, Inc. operates as a clinical-stage life science company that focuses on therapies for cardiovascular, oncology, and infectious diseases. The company was founded by Roman Schenk and is headquartered in San Francisco, CA.
1
| Private Company | Pharmaceuticals: Major | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Roman Schenk tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| NEPHROGENEX INC | Medical Distributors | Chief Operating Officer | |
CardioPolymers, Inc.
 CardioPolymers, Inc. Pharmaceuticals: MajorHealth Technology CardioPolymers, Inc. provides novel biocompatible polymer implant therapies to treat cronic heart failures. The company was founded in 2003 and is headquartered in Laguna Hills, CA. | Pharmaceuticals: Major | Chief Operating Officer | |
| The Trustees of Columbia University in The City of New York | College/University | Masters Business Admin | |
| The University of Texas at Austin | College/University | Undergraduate Degree | |
| Chimeric Therapies, Inc. | Corporate Officer/Principal | ||
| EDWARDS LIFESCIENCES CORPORATION | Medical Specialties | Corporate Officer/Principal | |
MateraCor, Inc.
 MateraCor, Inc. Medical SpecialtiesHealth Technology Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022. | Medical Specialties | Chief Executive Officer |
Statistiche
Distribuzione geografica
| Stati Uniti | 10 |
Settori
| Health Technology | 4 |
| Distribution Services | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Posizioni
| Chief Operating Officer | 4 |
| President | 3 |
| Corporate Officer/Principal | 2 |
| Masters Business Admin | 1 |
| Undergraduate Degree | 1 |
Contatti più connessi
| Insiders | |
|---|---|
| Frank A. Ahmann | 10 |
- Borsa valori
- Insiders
- Roman Schenk
- Connessioni Società
